Metropolitan Life Insurance CO Silverback Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	N/A	67 Added 4.69%	1,495 $0
Q2 2023 Aug 10, 2023	BUY	N/A	1,428 New	1,428 $0
Q4 2021 Feb 15, 2022	SELL	$6.03 - $11.67 $38,489 - $74,489	-6,383 Closed	0 $0
Q3 2021 Jun 21, 2023	BUY	$9.98 - $35.22 $63,702 - $224,809	6,383 New	6,383 $63,000
Q3 2021 Mar 30, 2023	BUY	$9.98 - $35.22 $24,560 - $86,676	2,461 Added 62.75%	6,383 $63,000
Q3 2021 Nov 15, 2021	BUY	$9.98 - $35.22 $24,560 - $86,676	2,461 Added 62.75%	6,383 $64,000
Q2 2021 Mar 30, 2023	SELL	$24.71 - $44.28 $2,866 - $5,136	-116 Reduced 2.87%	3,922 $121,000
Q2 2021 Aug 16, 2021	BUY	$24.71 - $44.28 $96,813 - $173,489	3,918 Added 97950.0%	3,922 $121,000
Q1 2021 Jun 26, 2023	BUY	$37.62 - $60.41 $151,909 - $243,935	4,038 New	4,038 $176 Million
Q1 2021 Mar 30, 2023	BUY	$37.62 - $60.41 $151,909 - $243,935	4,038 New	4,038 $176,000
Q1 2021 May 14, 2021	BUY	$37.62 - $60.41 $150 - $241	4 New	4 $176,000

163

62.7M

872K

589K

Ticker SBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,473,800
Description
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.